今天是:2019-07-17 星期三

以GLP-1为基础的药物对初发肥胖2型糖尿病患者胰岛素抵抗的改善及作用机制研究
下载XML文档

注册号:

Registration number:

ChiCTR1900020647 

最近更新日期:

Date of Last Refreshed on:

2019-01-11 

注册时间:

Date of Registration:

2019-01-11 

注册号状态:

预注册  

Registration Status:

Prospective registration  

注册题目:

以GLP-1为基础的药物对初发肥胖2型糖尿病患者胰岛素抵抗的改善及作用机制研究 

Public title:

Study for GLP-1-based drugs on improving insulin sensitivity in newly diagnosis obese type 2 diabetic patients 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

以GLP-1为基础的药物对初发肥胖2型糖尿病患者胰岛素抵抗的改善及作用机制研究 

Scientific title:

Study for GLP-1-based drugs on improving insulin sensitivity in newly diagnosis obese type 2 diabetic patients 

研究课题代号(代码):

Study subject ID:

 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

施梦特 

研究负责人:

施梦特 

Applicant:

Shi Mengte 

Study leader:

Shi Mengte 

申请注册联系人电话:

Applicant telephone:

+86 13706673733 

研究负责人电话:

Study leader's telephone:

+86 13706673733 

申请注册联系人传真 :

Applicant Fax:

 

研究负责人传真:

Study leader's fax:

 

申请注册联系人电子邮件:

Applicant E-mail:

smt198853@163.com 

研究负责人电子邮件:

Study leader's E-mail:

smt198853@163.com 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

中国浙江省温州市学院西路109号 

研究负责人通讯地址:

中国浙江省温州市学院西路109号 

Applicant address:

109 Xueyuan Road West, Wenzhou, Zhejiang, China 

Study leader's address:

109 Xueyuan Road West, Wenzhou, Zhejiang, China 

申请注册联系人邮政编码:

Applicant postcode:

 

研究负责人邮政编码:

Study leader's postcode:

 

申请人所在单位:

温州医科大学附属第二医院 

Applicant's institution:

Department of Endocrinology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University 

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

KYKT2018-112 

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

温州医科大学附属第二医院医学伦理委员会 

Name of the ethic committee:

the ethics committee of The Second Affiliated Hospital of Wenzhou Medical University 

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 

伦理委员会联系人:

朱雪琼 

Contact Name of the ethic committee:

Zhu Xueqiong 

伦理委员会联系地址:

中国浙江省温州市学院西路109号 

Contact Address of the ethic committee:

109 Xueyuan Road West, Wenzhou, Zhejiang, China 

伦理委员会联系人电话:

Contact phone of the ethic committee:

 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

 

研究实施负责(组长)单位:

温州医科大学附属第二医院 

Primary sponsor:

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University 

研究实施负责(组长)单位地址:

中国浙江省温州市学院西路109号 

Primary sponsor's address:

109 Xueyuan Road West, Wenzhou, Zhejiang, China 

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

温州市

Country:

China

Province:

Zhejiang

City:

Wenzhou

单位(医院):

温州医科大学附属第二医院

具体地址:

中国浙江省温州市学院西路109号

Institution
hospital:

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Address:

109 Xueyuan Road West, Wenzhou, Zhejiang, China

经费或物资来源:

温州医科大学附属第二医院 

Source(s) of funding:

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University 

研究疾病:

糖尿病 

Target disease:

diabetes 

研究疾病代码:

 

Target disease code:

 

研究类型:

干预性研究 

Study type:

Interventional study 

研究所处阶段:

上市后药物 

Study phase:

研究目的:

本研究围绕关键问题“以GLP-1为基础的药物能否改善肥胖2型糖尿病患者骨骼肌微循环容量和胰岛素抵抗状态”,为其改善胰岛素抵抗作用机制提供相关的临床依据,对制定该类药物更完善的临床适用范围起到一定理论依据。 

Objectives of Study:

To investigate the influence of GLP-1-based drugs on the muscular microcirculation and insulin resistance in in newly diagnosed obese type 2 diabetic patients